In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart ...

Pills like metformin, sulfonylureas, and DPP-4 inhibitors help lower blood ... What are the potential side effects, and how can I manage them? Every medicine can have side effects.

Sir Keir Starmer was on Wednesday night accused of an “act of cowardice” after Labour MPs lined up to block a national inquiry into grooming gangs. MPs voted by 364 votes to 111 against Kemi ...

To push this field forward, we need an integrated approach to study effects in both human and preclinical models ... peptide-1 receptor agonist (GLP-1RA), a dipeptidyl peptidase-4 inhibitor (DPP-4i) ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Based on the study, the researchers reported the following findings: The weighted cohort included 76,072 episodes of SGLT2i use and 75,833 episodes of DPP-4i use. The median age was 69, with an HbA1c ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

While Aloe Vera gel is touted as a natural and harmless ingredient, the title warns of potential side effects when applied to the face. Why? The truth lies in the fact that some natural ingredients, ...

Although the DPP official did not provide a specific date to our correspondent during a conversation on Wednesday, he said the case would be filed this week. The DPP’s decision is suspected to ...